Dr Jenn King joins Exopharm Board
Exopharm Limited (ASX: EX1) is pleased to announce the appointment of Dr Jennifer (Jenn) King to the Exopharm Board, effective… Read more
Nyrada Inc (ASX:NYR) Full Year Results FY21
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
Exopharm Science Webinar – Overcoming the Nucleic Acid Delivery Challenge
Exosome medicine company Exopharm Limited (ASX: EX1) is pleased to advise that it will host a webinar on Thursday, 26… Read more
Incannex NOTICE OF EXTRAORDINARY GENERAL MEETING
Incannex files registration statement with the SEC for proposed initial public offering in the United States
HTG: VESSEL REDELIVERY SHINES SPOTLIGHT ON TECHNOLOGY
NYR In Vivo Trial Results Show Further Positive Results
Last Friday, Nyrada released further positive results from an animal trial using a mouse model genetically modified to mimic human-like… Read more
ReNerve Shareholder Newsletter August 2021
Some notable highlights : Presentation of ReNerve at the Royal Australian College of Surgeons Annual Scientific Meeting in Melbourne Launch… Read more
